A-2B530 is under clinical development by A2 Biotherapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how A-2B530’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

A-2B530 overview

A-2B530 is under development for the treatment of solid tumor including metastatic colorectal cancer, lung cancer and pancreatic cancer. The therapy constitutes of genetically manipulated autologous Tmod (T-cell module) T cells which express chimeric antigen receptors (CAR) targeting cells expressing tumor antigens. It acts by targeting CEA and HLA-A02 (HLA-A2). It is administered through intravenous route.

A2 Biotherapeutics overview

A2 Biotherapeutics (A2) is a biotechnology company, focused on cell therapy, that aspires to beat cancer via tumor-specific targeting. It is headquartered in Agoura Hills, California, the US.

For a complete picture of A-2B530’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.